216 related articles for article (PubMed ID: 31256368)
1. Alpelisib: First Global Approval.
Markham A
Drugs; 2019 Jul; 79(11):1249-1253. PubMed ID: 31256368
[TBL] [Abstract][Full Text] [Related]
2. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
Rugo HS; Lerebours F; Ciruelos E; Drullinsky P; Ruiz-Borrego M; Neven P; Park YH; Prat A; Bachelot T; Juric D; Turner N; Sophos N; Zarate JP; Arce C; Shen YM; Turner S; Kanakamedala H; Hsu WC; Chia S
Lancet Oncol; 2021 Apr; 22(4):489-498. PubMed ID: 33794206
[TBL] [Abstract][Full Text] [Related]
3. Is Alpelisib Plus Fulvestrant Cost-Effective for Treating PIK3CA-Mutation, HR+/HER2- Advanced Breast Cancer in the USA?
Wu W; Lin H; Cai J; Sun H; Liu J; Hu C; Wei X
Clin Drug Investig; 2023 Dec; 43(12):939-948. PubMed ID: 37975961
[TBL] [Abstract][Full Text] [Related]
4. Capivasertib: First Approval.
Shirley M
Drugs; 2024 Mar; 84(3):337-346. PubMed ID: 38388873
[TBL] [Abstract][Full Text] [Related]
5. Biology and Targetability of the Extended Spectrum of PIK3CA Mutations Detected in Breast Carcinoma.
Rugo HS; Raskina K; Schrock AB; Madison RW; Graf RP; Sokol ES; Sivakumar S; Lee JK; Fisher V; Oxnard GR; Tukachinsky H
Clin Cancer Res; 2023 Mar; 29(6):1056-1067. PubMed ID: 36321996
[TBL] [Abstract][Full Text] [Related]
6. Alpelisib for PIK3CA-mutated advanced gynecological cancers: First clues of clinical activity.
Passarelli A; Carbone V; Pignata S; Mazzeo R; Lorusso D; Scambia G; Canova S; Di Palma T; Tasca G; Mantiero M; Naglieri E; Andreetta C; Rauso M; Brunetti AE; Laera L; Abeni C; Scandurra G; Gambaro AR; Pastore A; Bengala C; Gunnellini M; Farolfi A; Spinello M; Bartoletti M
Gynecol Oncol; 2024 Apr; 183():61-67. PubMed ID: 38518529
[TBL] [Abstract][Full Text] [Related]
7. Alpelisib-Induced Diabetic Ketoacidosis: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System and Review of the Literature.
Ziegengeist JL; Elmes JB; Strassels SA; Patel JN; Moore DC
Clin Breast Cancer; 2024 Jun; 24(4):e204-e209. PubMed ID: 38245400
[TBL] [Abstract][Full Text] [Related]
8. Incidence, risk factors, and management of alpelisib-associated hyperglycemia in metastatic breast cancer.
Shen S; Chen Y; Carpio A; Chang C; Iyengar NM
Cancer; 2023 Dec; 129(24):3854-3861. PubMed ID: 37743730
[TBL] [Abstract][Full Text] [Related]
9. A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breast cancer.
Rodón J; Demanse D; Rugo HS; Burris HA; Simó R; Farooki A; Wellons MF; André F; Hu H; Vuina D; Quadt C; Juric D
Breast Cancer Res; 2024 Mar; 26(1):36. PubMed ID: 38439079
[TBL] [Abstract][Full Text] [Related]
10. STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3Kα-Mutant Xenografts.
Buckbinder L; St Jean DJ; Tieu T; Ladd B; Hilbert B; Wang W; Alltucker JT; Manimala S; Kryukov GV; Brooijmans N; Dowdell G; Jonsson P; Huff M; Guzman-Perez A; Jackson EL; Goncalves MD; Stuart DD
Cancer Discov; 2023 Nov; 13(11):2432-2447. PubMed ID: 37623743
[TBL] [Abstract][Full Text] [Related]
11. [Toxic manifestations of alpelisib in endocrinology. Description of the clinical case].
Kudaeva LM; Kozhedub EE; Kupryshina VO; Aliyev TZ; Troshina EA
Probl Endokrinol (Mosk); 2023 Sep; 70(2):70-77. PubMed ID: 38796763
[TBL] [Abstract][Full Text] [Related]
12. Targeted therapy for capillary-venous malformations.
Zerbib L; Ladraa S; Fraissenon A; Bayard C; Firpion M; Venot Q; Protic S; Hoguin C; Thomas A; Fraitag S; Duong JP; Kaltenbach S; Balducci E; Lefevre C; Villarese P; Asnafi V; Broissand C; Goudin N; Nemazanyy I; Autret G; Tavitian B; Legendre C; Arzouk N; Minard-Colin V; Chopinet C; Dussiot M; Adams DM; Mirault T; Guibaud L; Isenring P; Canaud G
Signal Transduct Target Ther; 2024 Jun; 9(1):146. PubMed ID: 38880808
[TBL] [Abstract][Full Text] [Related]
13. Alpelisib for treatment of patients with PIK3CA-related overgrowth spectrum (PROS).
Canaud G; Lopez Gutierrez JC; Irvine AD; Vabres P; Hansford JR; Ankrah N; Branle F; Papadimitriou A; Ridolfi A; O'Connell P; Turner S; Adams DM
Genet Med; 2023 Dec; 25(12):100969. PubMed ID: 37634128
[TBL] [Abstract][Full Text] [Related]
14. Anticancer effects of alpelisib on PIK3CA-mutated canine mammary tumor cell lines.
Yeom J; Cho Y; Ahn S; Jeung S
Front Vet Sci; 2023; 10():1279535. PubMed ID: 38033642
[TBL] [Abstract][Full Text] [Related]
15. A comprehensive review of small molecules targeting PI3K pathway: Exploring the structural development for the treatment of breast cancer.
Dubey R; Sharma A; Gupta S; Gupta GD; Asati V
Bioorg Chem; 2024 Feb; 143():107077. PubMed ID: 38176377
[TBL] [Abstract][Full Text] [Related]
16. Alpelisib for PIK3CA-Mutated Advanced Breast Cancer.
Copur MS; Jonglertham P
N Engl J Med; 2019 Aug; 381(7):686-687. PubMed ID: 31412192
[No Abstract] [Full Text] [Related]
17. Alpelisib for PIK3CA-Mutated Advanced Breast Cancer.
Park J; Shin SW
N Engl J Med; 2019 Aug; 381(7):686. PubMed ID: 31412191
[No Abstract] [Full Text] [Related]
18. A New Wave of PI3Kα Inhibitors.
Kearney AL; Vasan N
Cancer Discov; 2023 Nov; 13(11):2313-2315. PubMed ID: 37909093
[TBL] [Abstract][Full Text] [Related]
19. Acrofacial vitiligo secondary to PI3KCA inhibitor, alpelisib: case report.
Hinich MG; Hijab A
Front Oncol; 2023; 13():1255832. PubMed ID: 37965451
[TBL] [Abstract][Full Text] [Related]
20. FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum.
Singh S; Bradford D; Li X; Mishra-Kalyani PS; Shen YL; Wang L; Zhao H; Xiong Y; Liu J; Charlab R; Kraft J; Khasar S; Miller CP; Rivera DR; Kluetz PG; Pazdur R; Beaver JA; Singh H; Donoghue M
Clin Cancer Res; 2024 Jan; 30(1):23-28. PubMed ID: 37624421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
